Organogenesis Holdings Inc has a consensus price target of $10.75 based on the ratings of 6 analysts. The high is $25 issued by Credit Suisse on August 10, 2021. The low is $3.5 issued by Morgan Stanley on November 14, 2023. The 3 most-recent analyst ratings were released by Lake Street, Cantor Fitzgerald, and Cantor Fitzgerald on June 28, 2024, March 1, 2024, and February 7, 2024, respectively. With an average price target of $5 between Lake Street, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied 54.80% upside for Organogenesis Holdings Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/28/2024 | Buy Now | 54.8% | Lake Street | Brooks O'Neil | → $5 | Initiates | → Buy | Get Alert |
03/01/2024 | Buy Now | 54.8% | Cantor Fitzgerald | Ross Osborn | → $5 | Reiterates | Overweight → Overweight | Get Alert |
02/07/2024 | Buy Now | 54.8% | Cantor Fitzgerald | Ross Osborn | → $5 | Initiates | → Overweight | Get Alert |
12/27/2023 | Buy Now | 85.76% | BTIG | Ryan Zimmerman | $4 → $6 | Maintains | Buy | Get Alert |
11/14/2023 | Buy Now | 8.36% | Morgan Stanley | Drew Ranieri | $3 → $3.5 | Maintains | Equal-Weight | Get Alert |
08/11/2023 | Buy Now | -7.12% | Morgan Stanley | Drew Ranieri | $5 → $3 | Maintains | Equal-Weight | Get Alert |
08/10/2023 | Buy Now | 23.84% | BTIG | Ryan Zimmerman | $10 → $4 | Maintains | Buy | Get Alert |
06/15/2023 | Buy Now | 54.8% | Morgan Stanley | Drew Ranieri | → $5 | Initiates | → Equal-Weight | Get Alert |
05/24/2023 | Buy Now | 209.6% | BTIG | Ryan Zimmerman | → $10 | Upgrade | Neutral → Buy | Get Alert |
11/10/2022 | Buy Now | — | BTIG | Ryan Zimmerman | — | Downgrade | Buy → Neutral | Get Alert |
11/10/2021 | Buy Now | 519.2% | SVB Leerink | Danielle Antalffy | — | Maintains | Outperform | Get Alert |
08/10/2021 | Buy Now | 673.99% | Credit Suisse | Matt Miksic | — | Maintains | Outperform | Get Alert |
The latest price target for Organogenesis Hldgs (NASDAQ:ORGO) was reported by Lake Street on June 28, 2024. The analyst firm set a price target for $5.00 expecting ORGO to rise to within 12 months (a possible 54.80% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Organogenesis Hldgs (NASDAQ:ORGO) was provided by Lake Street, and Organogenesis Hldgs initiated their buy rating.
The last upgrade for Organogenesis Holdings Inc happened on May 24, 2023 when BTIG raised their price target to $10. BTIG previously had a neutral for Organogenesis Holdings Inc.
The last downgrade for Organogenesis Holdings Inc happened on November 10, 2022 when BTIG changed their price target from N/A to N/A for Organogenesis Holdings Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Organogenesis Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Organogenesis Hldgs was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
While ratings are subjective and will change, the latest Organogenesis Hldgs (ORGO) rating was a initiated with a price target of $0.00 to $5.00. The current price Organogenesis Hldgs (ORGO) is trading at is $3.23, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.